MGI Tech Co., Ltd. (referred to as MGI) announced that it has entered into a comprehensive cooperation with AddLife AB, one of Europe's largest clinical testing and laboratory equipment channel providers based in Stockholm, Sweden, to accelerate the expansion of MGI's sequencing instrument and laboratory automation equipment in the Nordic region.

Kai Rantanen, Head of Clinical Testing Business of AddLife AB, and Yu Dejian, President of MGI, witnessed the signing of the agreement and exchanged views on further expansion of cooperation in Point-of-Care Testing (POCT), such as remote ultrasound robots. 

Under the agreement, four Triolab Group subsidiaries of AddLife AB, namely Triolab Sweden, Triolab Norway, Triolab Denmark (Iceland) and Triolab Finland, will act as independent agents to distribute MGI's sequencers, automation equipment, reagents and consumables in the four countries.

Europe has long been a significant market and technological area for life sciences and is one of the key strategic global markets that MGI continues to cultivate.

The Nordic countries are always renowned for their excellent healthcare services. Taking Sweden as an example, in 2018 Sweden launched the Genomic Medicine Sweden (GMS) initiative to establish seven regional genomic medicine centres, aiming to translate genomics innovations into clinical practice and planning to sequence 65,000 samples annually by 2025, covering most rare diseases and cancer patients in Sweden.

As of December 31, 2022, MGI has a presence in more than 90 countries and regions across six continents, with R&D, manufacturing bases and localized sales and marketing service teams in many countries and regions, serving over 2,000 users worldwide.

This collaboration is an important step for MGI to promote genomics accessibility and respond to the changing healthcare needs in the Nordic region. The two companies will complement each other to bring advanced genomics sequencing technologies and products to more local medical institutions and research institutes, accelerate the progress of genomics research and innovation in related fields, and improve the capability of genomics medicine and the quality of life of people in the Nordic region.